Structure Therapeutics Inc
NASDAQ:GPCR
Fundamental Analysis

Revenue & Expenses Breakdown
Structure Therapeutics Inc
Balance Sheet Decomposition
Structure Therapeutics Inc
Current Assets | 849.6m |
Cash & Short-Term Investments | 836.9m |
Other Current Assets | 12.7m |
Non-Current Assets | 16.9m |
PP&E | 10.8m |
Other Non-Current Assets | 6.1m |
Free Cash Flow Analysis
Structure Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Structure Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-182.5m
USD
|
Operating Income
|
-182.5m
USD
|
Other Expenses
|
39.2m
USD
|
Net Income
|
-143.3m
USD
|
GPCR Profitability Score
Profitability Due Diligence
Structure Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Structure Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GPCR Solvency Score
Solvency Due Diligence
Structure Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Structure Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GPCR Price Targets Summary
Structure Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GPCR is 80.22 USD with a low forecast of 50.5 USD and a high forecast of 126 USD.
Dividends
Current shareholder yield for GPCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?